174
Participants
Start Date
December 19, 2022
Primary Completion Date
November 21, 2024
Study Completion Date
November 21, 2024
SAR443820
Tablet by oral administration
Placebo
Tablet by oral administration
Investigational Site Number : 1000001, Sofia
Investigational Site Number : 1000002, Sofia
Investigational Site Number : 1000003, Sofia
Investigational Site Number : 0560003, Overpelt
Investigational Site Number : 0560002, Ghent
Investigational Site Number : 2500004, Caen
Investigational Site Number : 3800002, Milan
Investigational Site Number : 3800003, Milan
Investigational Site Number : 7240004, Madrid / Madrid
Investigational Site Number : 7240006, Madrid
Investigational Site Number : 7240003, Madrid
Investigational Site Number : 7240005, Murcia
Investigational Site Number : 7240002, Seville
Investigational Site Number : 2500003, Strasbourg
Investigational Site Number : 2500001, Paris
Investigational Site Number : 3800001, Pozzilli
Investigational Site Number : 2760002, Würzburg
Investigational Site Number : 1560002, Shanghai
Investigational Site Number : 1560001, Tianjin
Investigational Site Number : 1560003, Chengdu
Investigational Site Number : 1560004, Xi'an
Investigational Site Number : 1520001, Santiago
Investigational Site Number : 0560001, Brussels
Investigational Site Number : 1240002, Ottawa
Investigational Site Number : 1240004, Toronto
Investigational Site Number : 1240001, Gatineau
Investigational Site Number : 1240003, Lévis
Investigational Site Number : 2500002, Nice
Investigational Site Number : 3800005, Cagliari
Investigational Site Number : 6160004, Plewiska
Investigational Site Number : 6160002, Katowice
Investigational Site Number : 6160005, Katowice
Investigational Site Number : 6160001, Krakow
Investigational Site Number : 6160006, Zabrze
Investigational Site Number : 7240001, Barcelona
Lead Sponsor
Sanofi
INDUSTRY